Searched for
OVERACTIVE BLADDER DRUG
Zydus Lifesciences launches generic drug for overactive bladder in US marketZydus is among the first suppliers to launch the generic version of Mirabegron extended-release tablets (USP 25 mg) in the US market. The c...- Zydus unit recalls 7,248 bottles of Oxybutynin Chloride tablets in USNew Jersey-based Zydus Pharmaceuticals (USA) Inc. is recalling the affected lot due to "Failed Dissolution Specifications", the USFDA state...
- Zydus Lifesciences rises 4% on getting approval from USFDA for Mirabegron Tablets“Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Mirabegron Extend...
- Dr Reddy's Laboratories launches generic version of fesoterodine fumarate tablets in USThe company's fesoterodine fumarate extended-release tablets are available in 4 mg and 8 mg tablets, each in bottle count sizes of 30. Thes...
- Alembic Pharma gets tentative USFDA nod for fesoterodine fumarate extended-release tabletsThe approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for fesoterodine fumarate extende...
- Cipla recalls 7,228 bottles of overactive bladder treatment drug in AmericaAs per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or...
- Strides gets USFDA nod for generic Oxybutynin Chloride tabletsCompany's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets...
- Zydus Cadila gets USFDA nod for overactive bladder treatment drugThe company has received final approval from the United States Food and Drug Administration (USFDA) to market Solifenacin Succinate tablets...
- Granules India gets USFDA nod for overactive bladder treatment capsule"The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application filed by Granules Pharmaceuticals, Inc, a wh...
- Strides Pharma suspends sale of Ranitidine tab in USIn a regulatory filing, the company said it has received an Information Request from the USFDA to provide test data related to NDMA impurit...
- Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladderThe approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc.
- Alembic Pharma gets USFDA nod for overactive bladder treatment drugThe company has received approval from the USFDA for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the stren...
- Zydus Cadila gets tentative USFDA nod for overactive bladder treatment drugThe product will be manufactured at the group's manufacturing facility at SEZ in Ahmedabad.
- Alembic Pharmaceuticals gets USFDA go-ahead for bladder drugAccording to IMS December 2016 data, Darifenacin extended release tablets had an estimated market size of USD 64 million.
- Zydus Cadila gets USFDA nod for two drugsThe group has also received the tentative approval for Solifenacin Succinate tablets in strengths of 5 mg and 10 mg, Zydus Cadila said.
- USFDA gives nod to Zydus Cadila's overactive bladder tabletsThe drug is used to take care of an overactive bladder and urinary incontinence and will be produced at the group's formulation manufacturi...
- Glenmark Pharma's overactive bladder drug gets USFDA nodAccording to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 b...
- Cipla gets USFDA nod for overactive bladder treating drug"We have received final approval for ANDA for Darifenacin extended-release tablets, 7.5 mg and 15mg, from USFDA," a company statement said ...
- Astellas Pharma Q1 profit falls on R&D costsAstellas Pharma Inc Japan's second-largest drug maker, said on Friday its quarterly operating profit fell 5 percent on higher research and ...
- Pharma action hots up: UCB acquires Schwarz for $5.6bnUCB, the Belgian maker of the allergy drug Zyrtec, agreed to buy Schwarz Pharma for E4.4bn ($5.6bn) in cash and stock to gain new medicines...
Load More
